Navigation Links
Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
Date:2/25/2008

MONTVALE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its subsidiary, Duramed Pharmaceuticals, Inc., has received notification that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for Lo SEASONIQUE(R) (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg) extended-cycle oral contraceptive. The Company is seeking approval to manufacture and market the Lo SEASONIQUE, the first lower dose, extended-cycle oral contraceptive for the prevention of pregnancy. The Prescription Drug User Fee Action (PDUFA) date for the Lo SEASONIQUE NDA is October 24, 2008.

The clinical data supporting the Lo SEASONIQUE NDA resulted from one large pivotal multi-centered, open label clinical trial which concluded in June 2007. The clinical trial involved over 2,200 female subjects between the ages of 18 and 40 at 56 sites throughout the United States. Subjects were enrolled in the clinical trial for a duration of 12 months.

Under the Lo SEASONIQUE extended-cycle regimen, women take active tablets of 0.10 mg levonorgestrel/0.02 mg of ethinyl estradiol for 84 consecutive days, followed by seven days of 0.01 mg of ethinyl estradiol. The regimen is designed to reduce the number of withdrawal bleeding periods from 13 to four per year. By contrast, the majority of oral contraceptive products currently available in the United States are based on a regimen of 21 treatment days, followed by seven days of placebo.

Important Information About Oral Contraceptives

It is estimated that more than 16 million women currently take oral contraceptives in the United States. Oral contraceptives are not for every
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
2. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
3. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
4. Neuralstem Shares Accepted for Trading on Amex(R)
5. Attagenes Breakthrough Transcription Factor Profiling Technology to be Described in Nature Methods
6. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
7. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
8. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
9. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
10. Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
11. FDA Accepts Ranexa(R) sNDA and NDA for Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/17/2014)... York, NY (PRWEB) December 16, 2014 ... significant changes since 2013, which is why IBISWorld updated ... this industry continues to benefit from an intensified focus ... the proposal for new emission standards for power plants ... industry operators. According to IBISWorld Industry Analyst Sarah Kahn, ...
(Date:12/17/2014)... Achim Noack has been named global ... In this position, Noack will assist Jerry Stoller, CEO ... marketing strategy and supervise global marketing management and implementation ... tremendous knowledge and experience in the crop protection industry,” ... and innovative thinking will be a great asset for ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... (NASDAQ: ANPI , TSX: ANP), a global ... participate in the Bank of America,2008 Health Care ... Las Vegas,Nevada., Dr. William Hunter, Angiotech,s President ... Wednesday, May 14, beginning at approximately,4:00 pm Pacific ...
... Informed Clinical Sciences (ICS) Advisory,Services Corporation announced ... Property (IP) platform. This Platform suite offers ... an Alliance Business,Review, and a Health IT ... concerns, and enabling technologies underlying the growth ...
... VIAP ), a biotechnology company focused on the ... today that,James G. Stewart, senior vice president and chief ... & Renshaw 5th Annual Global,Healthcare Conference on Monday, May ... Plaza Hotel in Monte Carlo, Monaco., ...
Cached Biology Technology:IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 2IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance 3
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... of an animal food protein to a human protein determines ... scientists from the Institute of Food Research in Norwich and ... have the potential to become allergens, but the study found ... act as allergens depends on their evolutionary distance from a ...
... molecular pathway that plays a critical role in the ... an important insight into the development of the vascular ... for inhibiting the blood vessels that fuel cancers, diabetic ... study, published online on Oct. 14 in Nature Genetics. ...
... Lake Tahoe, CA, October 13, 2007Today at the Prostate ... findings on how eating common foods such as tomatoes ... cooked at high temperatures may help prevent prostate cancer, ... One in six men will be diagnosed with ...
Cached Biology News:Animal food allergens unmasked 2Study reveals a key to blood vessel growth and possible drug target 2Study reveals a key to blood vessel growth and possible drug target 3Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
Biology Products: